LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 246

Search options

  1. Article ; Online: The ISAQ Score Does Not Predict Adrenal Crisis in Patients with Primary Adrenal Insufficiency.

    Quinkler, Marcus / Kienitz, Tina

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association

    2022  Volume 130, Issue 8, Page(s) 554–560

    Abstract: Objective: This study aimed to investigate the ability of the immune system assessment questionnaire (ISAQ) to predict adrenal crisis (AC) and infectious events in patients with primary adrenal insufficiency (PAI).: Design: This was a prospective ... ...

    Abstract Objective: This study aimed to investigate the ability of the immune system assessment questionnaire (ISAQ) to predict adrenal crisis (AC) and infectious events in patients with primary adrenal insufficiency (PAI).
    Design: This was a prospective single-centre study over three years.
    Methods: Patients answered the ISAQ at baseline and were seen every 4-6 months in the endocrine outpatient clinic. At each visit previous infectious periods which required an increase in daily glucocorticoid dosage and AC were reported and documented. Seventy-five patients with PAI (53 women; 43 patients with autoimmune PAI, 20 patients with salt-wasting congenital adrenal hyperplasia and 12 patients who underwent bilateral adrenalectomy) were analysed. Due to the COVID-19 pandemic and consecutive lockdown measures, the data were analysed separately for March 2018 to March 2020 (period 1), and March 2020 to March 2021 (period 2).
    Results: During period 1 the ISAQ score significantly correlated with the number of reported infectious events (r=0.351; p<0.01), but not during period 2 (r=0.059, p=0.613), in which the number of infectious events per patient-year significantly decreased (1.1±0.1 vs 0.4±0.1; p<0.001). The frequency of AC decreased from 8.8 to 2.4 per 100 patient-years between the two study periods. The ISAQ score was not different between patients with or without AC.
    Conclusions: The ISAQ score does not identify patients prone to ACs. The COVID-19 pandemic and consecutive lockdown measures significantly diminished the frequency of infectious events and ACs.
    MeSH term(s) Addison Disease/epidemiology ; Adrenal Insufficiency/diagnosis ; Adrenal Insufficiency/epidemiology ; COVID-19 ; Communicable Disease Control ; Female ; Humans ; Pandemics ; Prospective Studies ; Surveys and Questionnaires
    Language English
    Publishing date 2022-03-03
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 1225416-2
    ISSN 1439-3646 ; 0947-7349
    ISSN (online) 1439-3646
    ISSN 0947-7349
    DOI 10.1055/a-1734-2466
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Mineralocorticoid replacement therapy in salt-wasting congenital adrenal hyperplasia.

    Lang, Katharina / Quinkler, Marcus / Kienitz, Tina

    Clinical endocrinology

    2023  

    Abstract: Patients with salt-wasting congenital adrenal hyperplasia (SW-CAH) usually show pronounced impairment of aldosterone secretion and, therefore, also require mineralocorticoid replacement. While a lot of research and discussion focusses on the ... ...

    Abstract Patients with salt-wasting congenital adrenal hyperplasia (SW-CAH) usually show pronounced impairment of aldosterone secretion and, therefore, also require mineralocorticoid replacement. While a lot of research and discussion focusses on the glucocorticoid therapy in SW-CAH to replace the missing cortisol and to control adrenal androgen excess, very little research is dealing with mineralocorticoid replacement. However, recent data demonstrated an increased cardiovascular risk in adult CAH patients urging to reflect also on the current mineralocorticoid replacement therapy. In this review, we explain the role and function of the mineralocorticoid receptor, its ligands and inhibitors and its relevance for the therapy of patients with SW-CAH. We performed an extensive literature search and present data on mineralocorticoid therapy in SW-CAH patients as well as clinical advice how to monitor and optimise mineralocorticoid replacement therapy.
    Language English
    Publishing date 2023-08-11
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 121745-8
    ISSN 1365-2265 ; 0300-0664
    ISSN (online) 1365-2265
    ISSN 0300-0664
    DOI 10.1111/cen.14959
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Book ; Thesis: Einflüsse durch ACTH und Steroide auf die menschliche renale 11beta-Hydroxysteroid-Dehydrogenase und die Charakterisierung der Isoenzyme der 11beta-Hydroxysteroid-Dehydrogenase in Leber und Niere des Meerschweinchens

    Quinkler, Marcus

    1998  

    Author's details vorgelegt von Marcus Quinkler
    Language German
    Size 139 S. : graph. Darst.
    Document type Book ; Thesis
    Thesis / German Habilitation thesis Berlin, Freie Univ., Diss., 1998
    HBZ-ID HT008880637
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  4. Article: In Response to: Prednisolone Replacement Therapy Mimics the Circadian Rhythm More Closely than Other Glucocorticoids.

    Quinkler, Marcus / Murray, Robert D

    The journal of applied laboratory medicine

    2020  Volume 1, Issue 6, Page(s) 753–755

    Language English
    Publishing date 2020-12-28
    Publishing country England
    Document type Journal Article
    ISSN 2576-9456
    ISSN 2576-9456
    DOI 10.1373/jalm.2016.022616
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: [No title information]

    Quinkler, Marcus / Kienitz, Tina

    Experimental and Clinical Endocrinology & Diabetes

    2022  Volume 130, Issue 08, Page(s) 554–560

    Abstract: Objective: This study aimed to investigate the ability of the immune system assessment questionnaire (ISAQ) to predict adrenal crisis (AC) and infectious events in patients with primary adrenal insufficiency (PAI). ...

    Abstract Objective: This study aimed to investigate the ability of the immune system assessment questionnaire (ISAQ) to predict adrenal crisis (AC) and infectious events in patients with primary adrenal insufficiency (PAI).
    Design: This was a prospective single-centre study over three years.
    Methods: Patients answered the ISAQ at baseline and were seen every 4–6 months in the endocrine outpatient clinic. At each visit previous infectious periods which required an increase in daily glucocorticoid dosage and AC were reported and documented. Seventy-five patients with PAI (53 women; 43 patients with autoimmune PAI, 20 patients with salt-wasting congenital adrenal hyperplasia and 12 patients who underwent bilateral adrenalectomy) were analysed. Due to the COVID-19 pandemic and consecutive lockdown measures, the data were analysed separately for March 2018 to March 2020 (period 1), and March 2020 to March 2021 (period 2).
    Results: During period 1 the ISAQ score significantly correlated with the number of reported infectious events (r=0.351; p<0.01), but not during period 2 (r=0.059, p=0.613), in which the number of infectious events per patient-year significantly decreased (1.1±0.1 vs 0.4±0.1; p<0.001). The frequency of AC decreased from 8.8 to 2.4 per 100 patient-years between the two study periods. The ISAQ score was not different between patients with or without AC.
    Conclusions: The ISAQ score does not identify patients prone to ACs. The COVID-19 pandemic and consecutive lockdown measures significantly diminished the frequency of infectious events and ACs.
    Keywords Addison’s disease ; ISAQ score ; AddiQoL ; adrenal crisis ; COVID-19 ; congenital adrenal hyperplasia
    Language English
    Publishing date 2022-03-03
    Publisher Georg Thieme Verlag KG
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 1225416-2
    ISSN 1439-3646 ; 0947-7349
    ISSN (online) 1439-3646
    ISSN 0947-7349
    DOI 10.1055/a-1734-2466
    Database Thieme publisher's database

    More links

    Kategorien

  6. Article ; Online: In reply.

    Quinkler, Marcus

    Deutsches Arzteblatt international

    2014  Volume 111, Issue 13, Page(s) 224

    MeSH term(s) Adrenal Insufficiency/diagnosis ; Adrenal Insufficiency/therapy ; Fluid Therapy/methods ; Hormone Replacement Therapy/methods ; Humans ; Hydrocortisone/administration & dosage
    Chemical Substances Hydrocortisone (WI4X0X7BPJ)
    Language English
    Publishing date 2014-04-16
    Publishing country Germany
    Document type Letter ; Comment
    ZDB-ID 2406159-1
    ISSN 1866-0452 ; 1866-0452
    ISSN (online) 1866-0452
    ISSN 1866-0452
    DOI 10.3238/arztebl.2014.0224b
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Recovery of adrenal function after stopping mitotane in patients with adrenocortical carcinoma.

    Altieri, Barbara / Kimpel, Otilia / Megerle, Felix / Detomas, Mario / Chifu, Irina / Fuss, Carmina Teresa / Quinkler, Marcus / Kroiss, Matthias / Fassnacht, Martin

    European journal of endocrinology

    2024  Volume 190, Issue 2, Page(s) 139–150

    Abstract: Objective: Mitotane is the standard therapy of adrenocortical carcinoma (ACC) due to its relative selectivity of its cytotoxic effects toward adrenocortical cells. Therefore, it virtually always leads to adrenal insufficiency. Frequency and ... ...

    Abstract Objective: Mitotane is the standard therapy of adrenocortical carcinoma (ACC) due to its relative selectivity of its cytotoxic effects toward adrenocortical cells. Therefore, it virtually always leads to adrenal insufficiency. Frequency and characteristics of hypothalamic-pituitary-adrenal axis recovery after discontinuation are ill-defined.
    Methods: This was a retrospective study of patients with ACC adjuvantly treated with mitotane for ≥12 months who were disease-free at mitotane stop and had a minimum follow-up ≥1 year. Primary endpoint was adrenal recovery. Cox regression analyses were used to identify predictive factors. Moreover, mitotane plasma elimination rate and hormonal changes after mitotane stop were investigated.
    Results: Fifty-six patients (36 women) treated with mitotane for a median time of 25 months and an average daily dose of 2.8 g were included. Median time after discontinuation until mitotane levels dropped below 5 and 2 mg/L, and the detection limit was 152 days (interquartile range: 114-202), 280 days (192-370), and 395 days (227-546), respectively. Full adrenal recovery was documented in 32 (57%) patients after a median time of 26 months (95% confidence interval [CI] = 19.6-32.4). In 4 patients (7.1%), adrenal insufficiency persisted >5 years after discontinuation. Mitotane peak ≥ 27 mg/L significantly correlated with longer time to adrenal recovery (hazard ratio [HR] = 0.2, 95% CI = 0.1-0.8, P = .03). Twenty-seven of 38 patients (71%) followed in reference centers achieved adrenal recovery compared with only 5/18 (28%) followed up in non-reference centers (HR = 4.51, 95% CI = 1.71-11.89, P = .002). Other investigated factors were not associated with adrenal function after discontinuation.
    Conclusions: Our study demonstrates that adrenal recovery occurs in most patients after stopping mitotane, particularly when followed up in specialized centers, but not in all. Elimination time of mitotane after treatment discontinuation is very long but individually quite variable.
    MeSH term(s) Humans ; Female ; Adrenocortical Carcinoma/drug therapy ; Mitotane/therapeutic use ; Adrenal Cortex Neoplasms/pathology ; Retrospective Studies ; Hypothalamo-Hypophyseal System ; Antineoplastic Agents, Hormonal/therapeutic use ; Pituitary-Adrenal System ; Adrenal Insufficiency/drug therapy
    Chemical Substances Mitotane (78E4J5IB5J) ; Antineoplastic Agents, Hormonal
    Language English
    Publishing date 2024-01-20
    Publishing country England
    Document type Journal Article
    ZDB-ID 1183856-5
    ISSN 1479-683X ; 0804-4643
    ISSN (online) 1479-683X
    ISSN 0804-4643
    DOI 10.1093/ejendo/lvae007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Adrenal disease: Imitating the cortisol profile improves the immune system.

    Müller, Lisa / Quinkler, Marcus

    Nature reviews. Endocrinology

    2018  Volume 14, Issue 3, Page(s) 137–139

    MeSH term(s) Adrenal Insufficiency ; Glucocorticoids ; Humans ; Hydrocortisone ; Immune System ; Immunity, Innate ; Single-Blind Method
    Chemical Substances Glucocorticoids ; Hydrocortisone (WI4X0X7BPJ)
    Language English
    Publishing date 2018-01-19
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 2489381-X
    ISSN 1759-5037 ; 1759-5029
    ISSN (online) 1759-5037
    ISSN 1759-5029
    DOI 10.1038/nrendo.2018.5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Häufiger als vermutet ist ein primärer Hyperaldosteronismus schuld : Trotz Kombinationstherapie bleibt der Blutdruck oben.

    Quinkler, Marcus

    MMW Fortschritte der Medizin

    2010  Volume 152, Issue 7, Page(s) 32–35

    Language German
    Publishing date 2010-02
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 1478211-x
    ISSN 1438-3276
    ISSN 1438-3276
    DOI 10.1007/BF03366113
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Therapie der Akromegalie – Daten aus dem Deutschen Akromegalie Register.

    Tönjes, Anke / Quinkler, Marcus / Knappe, Ulrich / Störmann, Sylvère / Schöfl, Christof / Schopohl, Jochen / Meyhöfer, Sebastian M

    Deutsche medizinische Wochenschrift (1946)

    2023  Volume 148, Issue 7, Page(s) 380–385

    Abstract: Acromegaly is a rare disease in which chronic growth hormone overproduction (usually from an anterior pituitary adenoma) leads to various systemic complications. The management of acromegaly and the comorbidities of the disease is complex and requires a ... ...

    Title translation Treatment of acromegaly - data from the German Acromegaly Register.
    Abstract Acromegaly is a rare disease in which chronic growth hormone overproduction (usually from an anterior pituitary adenoma) leads to various systemic complications. The management of acromegaly and the comorbidities of the disease is complex and requires a multidisciplinary approach. Early diagnosis is extremely important, as then the chances of a complete cure are significantly higher. The operation is the therapy of first choice and should be performed at a specialized center with an experienced neurosurgeon. With good patient information and guidance, the drug therapy of acromegaly patients in specialized practices and clinics can usually lead to biochemical control and thereby normalization of mortality risk. As with numerous rare diseases, care in specialized centers and recording and evaluation in registry studies can contribute to better patient care and the optimization of therapy and diagnostic guidelines. We assume that with the help of the German Acromegaly Registry, which currently includes more than 2500 patients with acromegaly, we will be able to present a realistic picture of the care situation in Germany in the coming years.
    MeSH term(s) Humans ; Acromegaly/diagnosis ; Acromegaly/epidemiology ; Acromegaly/therapy ; Adenoma/diagnosis ; Adenoma/epidemiology ; Adenoma/therapy ; Comorbidity ; Germany/epidemiology
    Language German
    Publishing date 2023-03-20
    Publishing country Germany
    Document type English Abstract ; Journal Article
    ZDB-ID 200446-x
    ISSN 1439-4413 ; 0012-0472
    ISSN (online) 1439-4413
    ISSN 0012-0472
    DOI 10.1055/a-1847-2553
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top